# A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Source: https://onco.cc/trials/nct05006716/  
OnCo record `nct05006716` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BGB-16673 in follicular lymphoma and hodgkin lymphoma, run by BeOne Medicines, now recruiting.

## Summary

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies is a phase 1/2 interventional study registered as NCT05006716 by BeOne Medicines, with 645 participants planned, started 2021-09-13 and due to reach its primary completion in 2026-11. Interventions recorded: Tacabrutideg. Conditions listed: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05006716
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
- Sponsor: BeOne Medicines
- Enrolled: 645

## Sources

- ClinicalTrials.gov NCT05006716: https://clinicaltrials.gov/study/NCT05006716

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [BGB-16673](https://onco.cc/drugs/bgb-16673/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/)

---
JSON: https://onco.cc/api/v1/entities/nct05006716.json